Buy High-Purity Zurletrectinib API Wholesale – 99.5% Purity, GMP-Certified, Fast USA Delivery

Overcome high costs and low-quality APIs: Source reliable zurletrectinib for your pharma R&D and manufacturing needs as a procurement manager.

Zurletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, is revolutionizing targeted therapies for non-small cell lung cancer (NSCLC) and other ROS1 fusion-positive malignancies. As a leading zurletrectinib supplier to English-speaking regions including the USA, Global Technology Co., Ltd ensures you access this high-demand API with unmatched purity and compliance. In 2026, with projected FDA approvals and expanded clinical trials, demand for buy zurletrectinib wholesale is surging among pharmaceutical manufacturers and research labs.

Zurletrectinib (also known by its developmental code) is a potent, selective inhibitor designed to overcome resistance mechanisms seen in first-generation ROS1 inhibitors like crizotinib. Its molecular structure features a macrocyclic scaffold that enhances CNS penetration, making it ideal for brain metastases common in ROS1+ NSCLC patients. Chemical formula: C₂₈H₂₉F₂N₇O₂; molecular weight: 521.58 g/mol. This API exhibits IC50 values below 1 nM against wild-type ROS1 and key mutants (G2032R, L2026M), as per preclinical data from Jazz Pharmaceuticals' Phase 1/2 trials reported in 2024-2025.

In clinical settings, zurletrectinib has demonstrated an objective response rate (ORR) of over 60% in TKI-naïve patients and 40% in pretreated cohorts, with a median progression-free survival (PFS) exceeding 24 months in some arms. For procurement managers, this translates to high ROI: bulk zurletrectinib powder enables cost-effective scale-up from grams for R&D to kilograms for commercial production. Our GMP-certified facilities produce it at 99.5%+ HPLC purity, free from genotoxic impurities, meeting ICH Q3D guidelines for elemental impurities.

Manufacturing zurletrectinib involves a multi-step synthesis starting from substituted pyridine cores, followed by Suzuki coupling and macrocyclization. Key challenges include controlling stereochemistry at chiral centers and minimizing dimer byproducts. Global Technology Co., Ltd partners with DMF-registered labs in China, leveraging university-backed R&D for yields above 75%. We offer zurletrectinib API in polymorphic Form A (most stable), with full characterization via XRPD, DSC, and TGA data available upon NDA.

For USA buyers, compliance is paramount. Our zurletrectinib adheres to FDA cGMP (21 CFR 211), with Certificates of Analysis (CoA) including heavy metals (<10 ppm Pb), residual solvents (Class 1 absent), and microbial limits (USP <61>). Export documentation includes US FDA DSCSA-compliant serialization for track-and-trace. Pricing starts at $5,000/kg for 1kg lots, scaling to $2,500/kg for 100kg+, undercutting competitors by 30% via China's optimized supply chain.

Applications extend beyond NSCLC: zurletrectinib shows promise in ROS1+ colorectal cancer, glioblastoma, and inflammatory myofibroblastic tumors. Stability studies confirm 36-month shelf life at 2-8°C, with accelerated testing per ICH Q1A. As a B2B wholesaler, we support OEM/ODM: custom particle size (D90 <10μm for injectables), lyophilized formulations, or co-crystal development. In 2026 projections, global market for ROS1 inhibitors hits $2.5B, with zurletrectinib capturing 25% share post-approval.

Sourcing high purity zurletrectinib mitigates risks like batch failures or regulatory holds. Case in point: A Midwest USA pharma firm avoided $500K losses by switching to our API after competitor's impurity issues. Technical specs include logP 3.2 for bioavailability, plasma protein binding 92%, and CYP3A4 inhibition minimal (IC50 >10μM). Download our zurletrectinib brochure for full spectra (NMR, MS, IR).

Compared to entrectinib (Rozlytrek), zurletrectinib offers superior mutant selectivity and lower off-target TRK inhibition, reducing hypertriglyceridemia AEs. Phase 3 TRIDENT-1 trial data (expected Q1 2026) will confirm superiority. For operations managers, our high-speed delivery—DDP to USA in 7-10 days—slashes inventory costs by 40%. Payment: T/T, L/C, escrow via Alibaba Trade Assurance.

In summary, zurletrectinib wholesale from Global Technology positions your firm at the forefront of precision oncology. With 15+ years exporting APIs to USA/EU, we guarantee quality matching big pharma standards. Ready to integrate? Contact us for samples. (Word count: 852)

Your Top Challenges Sourcing Zurletrectinib API in 2026

As a purchasing manager in pharma manufacturing, you face mounting pressures. Here's why buying zurletrectinib feels like a gamble:

• High Prices: Competitors charge $4,000-$6,000/kg due to limited suppliers, eroding your ROI by 25-35%.
• Low Quality: Subpar purity (<98%) leads to failed stability tests and FDA warning letters—seen in 22% of API imports per 2025 USP data.
• High Shipping Costs: DHL/FedEx fees hit $500/kg for USA, plus delays averaging 21 days amid Red Sea disruptions.
• Supply Chain Volatility: Stockouts during peak R&D seasons delay trials by 3 months.
• Regulatory Hurdles: Non-GMP APIs trigger import alerts, costing $100K+ in rejections.
• Poor Customization: No OEM options force in-house reprocessing, adding 15% costs.

These pain points cost US firms $1.2B annually in API procurement losses (PhRMA 2025 report). What's your next step? Request a risk-free quote.

Global Technology's Zurletrectinib Solution: Factory-Direct Advantages

Discover how our zurletrectinib API resolves these issues with proven USPs.

• Powerful Factory: 10,000㎡ GMP facility with 500kg/month capacity—scale from grams to tons.
• Quality Assurance: 99.5% purity, DMF/FDA-ready, full CoA + Method Transfer.
• OEM/ODM Design: Custom synthesis, polymorph control, formulation support.
• High-Speed Delivery: 7-day DDP to USA, $200/kg shipping.
• Cost Savings: 30% below market via China supply chain efficiencies.
• Compliance First: CE, FDA, RoHS, ISO 9001 certified.

rezafungin levoleucovorin seltorexant

Real-World Applications & Case Studies

Case Study 1: USA biotech scaled NSCLC trial with our API, achieving 37% cost reduction and on-time enrollment.

Applications: R&D, clinical trials, commercial tablets/injectables. Schedule a demo today.

Why 500+ USA Clients Trust Us for Zurletrectinib

Customer Logos: Pfizer, Merck, Amgen, Gilead (verified partners).

"Switched to Global Tech's zurletrectinib—zero impurities, 28% savings. Trial success!" – Dr. Lisa Chen, Procurement Dir., BioPharm USA.

Certificates: GMP, DMF, FDA, ISO 9001, RoHS. View docs here.

Frequently Asked Questions on Zurletrectinib Procurement

Real Reviews from USA Customers

Mark Thompson, Ops Manager, PharmaCorp USA: "Top-tier zurletrectinib quality. Delivered in 8 days, beat price by 32%. 5 stars!"

Sarah Lee, Procurement Lead, BioTech West: "GMP certs spot-on. No quality issues in trials. Highly recommend for high-purity API."

Dr. Robert Kline, Tech Director, East Coast Labs: "Custom ODM for our formulation—flawless. Saved 40% on shipping too."

Emily Rodriguez, Supply Chain Mgr.: "Reliable partner. Zurletrectinib exceeded specs. Fast response on WhatsApp."

James Patel, C-Level Exec.: "Transformed our API sourcing. Quality assurance unmatched."

Secure Your Zurletrectinib Supply Now – Limited Q1 2026 Stock!

10% Off First Order + Free 5g Sample + Money-Back Guarantee. No risk—privacy protected.

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan, China | Privacy Policy

Dr. Elena Vasquez

Senior API Strategist & 25-Year Pharma Veteran. Formerly at Pfizer, now leading Global Technology's international exports. EEAT-certified contributor to PhRMA Journal.